Yahoo · Nov 5, 2026
Sana: Q3 Earnings Snapshot
SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Thursday reported third-quarter earnings of $20.
NASDAQ · SANA
Healthcare · Biotechnology
$2.02
Down-$0.14 (-6.93%)
Updated Nov 17, 2026, 1:40 AM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SANA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
SANA closed at $2.02 after 20 trading sessions, down 12.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $2.05 | $2.05 | $1.8601 | $2.02 | 3.2M |
| Nov 12, 2026 | $2.25 | $2.25 | $2.00 | $2.01 | 3.69M |
| Nov 11, 2026 | $2.43 | $2.449 | $2.28 | $2.29 | 2.73M |
| Nov 10, 2026 | $2.42 | $2.52 | $2.31 | $2.43 | 2.54M |
| Nov 9, 2026 | $2.42 | $2.48 | $2.28 | $2.465 | 3.26M |
| Nov 6, 2026 | $2.49 | $2.49 | $2.2825 | $2.37 | 2.31M |
| Nov 5, 2026 | $2.53 | $2.53 | $2.28 | $2.34 | 3.09M |
| Nov 4, 2026 | $2.55 | $2.62 | $2.455 | $2.56 | 2.64M |
| Nov 3, 2026 | $2.43 | $2.52 | $2.40 | $2.44 | 1.82M |
| Nov 2, 2026 | $2.57 | $2.585 | $2.37 | $2.40 | 2.6M |
| Oct 30, 2026 | $2.68 | $2.72 | $2.51 | $2.57 | 2.08M |
| Oct 29, 2026 | $2.655 | $2.7678 | $2.65 | $2.72 | 3.31M |
| Oct 28, 2026 | $2.43 | $2.64 | $2.38 | $2.63 | 3.29M |
| Oct 27, 2026 | $2.37 | $2.48 | $2.33 | $2.47 | 2.62M |
| Oct 26, 2026 | $2.33 | $2.385 | $2.29 | $2.36 | 1.51M |
| Oct 23, 2026 | $2.35 | $2.38 | $2.245 | $2.33 | 1.71M |
| Oct 22, 2026 | $2.325 | $2.44 | $2.28 | $2.37 | 2.43M |
| Oct 21, 2026 | $2.38 | $2.39 | $2.315 | $2.35 | 2.4M |
| Oct 20, 2026 | $2.27 | $2.42 | $2.25 | $2.36 | 3.53M |
| Oct 19, 2026 | $2.32 | $2.3588 | $2.22 | $2.30 | 2.63M |
The latest Smart Investors Daily articles mentioning SANA.
Company
Market Activity
Research & News
SANA research
Company profile and research snapshot.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| Apr 14, 2026 | Wedbush | Outperform | — |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | B of A Securities | Buy | — |
| Nov 7, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 5, 2026
SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Thursday reported third-quarter earnings of $20.
Yahoo · Nov 5, 2026
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating
Benzinga · Nov 5, 2026
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 6.67 percent increase over losses of $(0.15) per share from
SeekingAlpha · Oct 13, 2026
Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. Check out why SANA stock is a buy.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning SANA.